Anaesthesia and Intensive Care最新文献

Tubeless microlaryngoscopy optimises surgical access but typically relies on total intravenous anaesthesia, commonly using propofol and remifentanil infusions. We present a difficult airway case where an unrecognised drug error during programming of an infusion pump resulted in unexpected apnoea. Open airway surgery proceeded with the use of a prophylactic cannula cricothyroidotomy using a Rapid-O2® insufflation device to provide rescue oxygenation. Furthermore, cricothyroid membrane identification failed with digital palpation but was successful with ultrasonography. While the latter is currently not considered the standard of care for preparing for front-of-neck access in a time-critical 'can't intubate, can't oxygenate' scenario, in our case it proved helpful.

Rates of misrepresenting smoking status on day of surgery varies with the clinical context. In perioperative smoking cessation trials, participants in the intervention group might be more likely to provide untruthful data about quitting when they have received substantial quit support but continued to smoke. The objective of this study was to determine misrepresentation rates of smoking status on day of surgery in mixed elective surgical populations, comparing groups offered or not offered additional cessation support. We undertook a post hoc analysis of data from three published randomised trials at a Melbourne public hospital that incorporated interventions during the wait-list period aimed at increasing smoking cessation. Participants were smokers (n = 1413) who were randomised to minimal cessation help at wait-listing (control group) or significant assistance, for example, mailed nicotine replacement (intervention group). Quit by day of surgery claims were verified by exhaled carbon monoxide (true cessation <8 parts per million). Verified cessation (>24 h) before surgery occurred in 161/1413 (11.4%) while 44/1413 (3.1%) misrepresented quitting. Continued smoking was in 1208/1413 (85.5%). Misrepresentations were higher in the intervention/offer of help groups (4.1%) than control groups (1.7%) (odds ratio (OR) 2.46, 95% confidence interval (CI) 1.17 to 5.63, P = 0.012). Offering cessation help increased quitting odds by 77%, (OR 1.77, 95% CI 1.24 to 2.52, P = 0.002). In contrast to other studies, we found group allocation in cessation trial settings had a significant effect on misrepresentation risk. The implication of this is that biochemical verification of quit status is essential in trial contexts for accurate data collection and to prevent misclassification bias.

The acquisition of an early ether inhaler stimulated research into several inhalers classified as Bruck inhalers. Ludwig Hermann Bruck was a German migrant who arrived in Australia in 1873. He became a medical publisher, importer of medical instruments, and made unique contributions to early Australian medical publishing, most significantly as the first publisher of The Australasian Medical Gazette. He also published The Australian Medical Directory and Handbook which contained lists of unregistered medical practitioners and alternative therapists. In 1914, Bruck joined in business with Richard Thomson who had a company selling medical equipment to doctors and hospitals. During the First World War, both Bruck and Thomson were charged with trading with the enemy. Bruck committed suicide in August 1915 before the case was heard in court. We did not find any evidence that Bruck designed the inhaler later attributed to him. The Bruck inhaler is functionally similar to the Probyn-Williams inhaler and should therefore be regarded as a glass-domed version of this inhaler.

An early administration of anaesthesia for childbirth occurred on 19 January 1847, when Scottish obstetrician James Young Simpson administered diethyl ether to facilitate the delivery of a child to a woman with a deformed pelvis. Simpson advocated for its use to reduce pain both in surgery and in childbirth. Obstetric anaesthesia was controversial for many reasons, and objections came not only from fellow obstetricians, but also from the public and members of the clergy. While James Young Simpson shed light upon religious objections to obstetric anaesthesia, modern scholars have debated whether such objections truly existed. The aim of this study is to determine whether religious objections to obstetric anaesthesia were endorsed by medical professionals in France during the mid-19th century. A search of the Bibliothèque Nationale de France (National Library of France) was conducted. Primary source documents reveal that French physicians were interested in studying the effects of ether and chloroform during labour and delivery. Nevertheless, the introduction of obstetric anaesthesia was controversial for many reasons, including concerns about its effect on natural labour. The evidence suggests that these objections were not endorsed by the medical community. Much of the controversy surrounding obstetric anaesthesia involved the perceived necessity of the practice during low-risk vaginal deliveries. It appears that French physicians were aware of religious objections to the use of anaesthesia in childbirth but did not endorse them. The use of obstetric anaesthesia in France was guided by scientific evidence and clinical experience, without interference from religious leaders.

Sleep, dreams, unconsciousness and death are concepts regularly contended with by anaesthetists and their patients. The closely related genealogy of the entities personifying these concepts in ancient Greek mythology highlights a visceral uncertainty about the spectrum of human unconsciousness. Hypnos and Thanatos-Sleep and Death, respectively-commonly feature together in art and literature as twin brothers. Sleep was the more powerful of the two and was feared even by members of the Pantheon immune to death such as Zeus himself, drawing a parallel with the modern knowledge that all living organisms demonstrate susceptibility to anaesthesia. The power to induce sleep was regarded as a divine ability and was thus the domain of the gods. However, some mortals possessed these talents, usually through application of herbs or potions, highlighting an understanding that a state of unconsciousness could be induced by elements from the environment in the hands of a skilled or gifted operator. Through multiple different tales, the ancient Greeks also imply a distinction between physiological and drug-induced sleep, the latter of which is frequently associated with wrath and amnesia. Despite this distinction, sleep is commonly used interchangeably with general anaesthesia in discussions with patients. Though presumably intentioned to provide reassurance, using inaccurate terminology may impact on patients' ability to make an informed decision about receiving an anaesthetic. Perhaps there is a role for artistic and allegorical methods of communication to reflect this distinction to patients as we guide them through an odyssey of their own into a state of controlled unconsciousness.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes and/or obesity. The physiological actions of endogenous GLP-1, and synthetic GLP-1RAs include inhibition of gastric emptying. This has peri-procedural implications due to the potential increased risk of retained gastric contents which may result in pulmonary aspiration. There is a need for local evidence-based guidelines to best manage patients on GLP-1RAs and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonists (GLP-1/GIPRAs) presenting for surgical and medical procedures requiring sedation or anaesthesia. A panel of experts was formed to consider the peri-procedural implications of GLP-1RA and GLP-1/GIPRA use and establish best practice recommendations based on the current evidence.We recommend that all patients should be asked about glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist (GLP-1/GIPRA) use prior to anaesthesia or sedation for surgical and endoscopic procedures and be informed of the benefits and risks. We also recommend that GLP-1RAs and GLP-1/GIPRAs be continued in the peri-procedural period. Preprocedural diet modification with a 24-h clear fluid diet, followed by standard 6-h fasting, should be recommended for all patients receiving GLP-1RAs or GLP-1/GIPRAs. In patients who have not completed or are unable to have a 24-h liquid diet, risk stratification using gastric ultrasound or minimally sedated gastroscopy to assess gastric contents is recommended, as is the use of intravenous erythromycin. We cannot currently recommend using the absence of gastrointestinal symptoms for risk stratification, nor can we recommend an adequate cessation period for GLP-1RAs and GLP-1/GIPRAs to ensure gastric emptying has returned to baseline levels. This clinical guideline, developed by multiple professional bodies, outlines current best practice recommendations for patients taking GLP-1RAs and combined GLP-1/GIPRAs who require general anaesthesia, sedation and/or endoscopic procedures. The guide provides a structure for Australian and New Zealand primary health practitioners, gastroenterologists, surgeons, endocrinologists, anaesthetists and perioperative physicians to support clinical decisions in these patients.

This study aimed to characterise specialist palliative care service involvement within the intensive care unit (ICU) and subsequently in post-ICU hospital wards, and compare current ICU referral practices with those suggested by an internationally utilised ICU palliative care referral tool. This was a retrospective cohort study, carried out at a large university-associated ICU in Melbourne, Australia, and was conducted on adult patients aged at least 18 years admitted to ICU between July 2019 and July 2023. The study included 11,449 ICU admission episodes relating to 10,171 patients. The overall ICU mortality for all patients was 9% in ICU with a further 4.3% post-ICU. Within non-survivors, specialist palliative care involvement was uncommon for patients who died in ICU (78/1035, 7.5%), but substantial (287/488, 59%) for those ICU patients who died on a hospital ward after ICU discharge. Compared with ICU patients who did not have an identified palliative care referral, ICU patients with palliative care input averaged longer ICU stays with shorter hospital stays post-ICU discharge. The referral tool showed low sensitivity (39%) when compared with observed current ICU palliative care referral practice. Clinical staff within the ICU provided the majority of palliative care for ICU patients, with a palliative care consultative service taking a proportionally much greater role in post-ICU hospital wards. The selected criteria appeared inadequate for use as an effective referral tool. Future research may explore the quality of palliative care provided by ICU staff and specialist palliative care staff, and the role of decision support tools, so as to provide optimal care for critically ill patients approaching the end of life.